BPC-157 Research in 2026: What the Evidence Actually Shows

Of 544 records screened in the 2025 systematic review, one clinical study survived inclusion — a retrospective series of twelve patients.

BPC-157 is among the most discussed compounds in the research peptide market and among the least tested in humans. Both of those things are true at once, and most writing about it manages to convey only the first.

This article is an attempt at the second. Peptides Exchange sells research peptides, BPC-157 among them, which is a reason to be skeptical of anything here that sounds like enthusiasm — so where the evidence is thin, this piece says so plainly and cites the review that establishes it.

For the compound’s basic profile, see What Is BPC-157?. If you are new to this category, What Are Research Peptides? is the better starting point.

Chemistry and origin

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — corresponding to a partial sequence of body protection compound, a protein identified in human gastric juice. The synthetic fragment was developed to study that activity in isolation.

Property	Value
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
One-letter	GEPPPGKPADDAGLV
Length	15 amino acids
Molecular formula	C₆₂H₉₈N₁₆O₂₂
Molecular weight	≈ 1419.6 g/mol
CAS number	137525-51-0
Other designations	Body Protection Compound 157, bepecin, PL 14736, PL-10, PLD-116
First reported	Sikiric and colleagues, Zagreb, 1993
Approval status	None, in any jurisdiction

Two structural details matter for anyone handling it.

Four prolines in fifteen residues. Proline’s cyclic side chain constrains the backbone and resists cleavage by many common proteases, which is the structural basis for the stability often attributed to this peptide. That is a statement about chemistry, not about what happens in an organism.

No cysteines, no disulfide. Unlike many peptides in this market, BPC-157 has no intramolecular bridge to scramble and no methionine to oxidize. Its analytical profile is correspondingly simpler than, say, MOTS-c, whose two methionines and tryptophan create oxidation species that complicate purity assessment.

The compound also appears under its former pharmaceutical development codes. PL 14736 was the designation under which the Croatian firm Pliva pursued it for inflammatory bowel indications. Literature searches that miss those synonyms miss part of the record.

What the systematic review found

This is the section most articles about BPC-157 do not contain, and it is the one that actually answers the question in the title.

In 2025, a group at Case Western and the Hospital for Special Surgery published a systematic review of BPC-157 in orthopaedic sports medicine (Vasireddi N, Hahamyan H, Salata MJ, et al. HSS J. 2025;21(4):485–495). They searched PubMed, Embase and Cochrane for work on the compound’s mechanism, musculoskeletal effects, metabolism and safety.

The numbers are the finding:


Records screened	544
Studies meeting inclusion criteria	36
Preclinical — animal and in vitro	35
Clinical — human	1

That single clinical study is a retrospective series of 12 patients with chronic knee pain, of whom seven reported subjective improvement. It is not a controlled trial. It has no comparison group, no blinding, and no objective endpoint.

The review’s own characterizations are worth quoting rather than paraphrasing. The included evidence was rated level IV and level V — the bottom of the evidence hierarchy. Heterogeneity in study design, objectives and outcome measures prevented quantitative meta-analysis. The authors found no human safety data. And they concluded that the absence of clinical outcome and safety data prevents the formation of evidence-based practice guidelines, advising that “clinicians and athletes should exercise caution when considering the use of BPC-157.”

One thing to notice about how that paper reads. Its abstract says BPC-157 “shows promise for promoting recovery from musculoskeletal injuries,” which is considerably warmer than its discussion and conclusion. That gap between abstract and body is itself instructive: the optimistic sentence is the one that gets quoted on product pages, and the cautionary paragraphs are the ones that get left behind. If you only ever encounter this literature through vendor summaries, you are reading abstracts.

The concentration problem

A second feature of this body of work is rarely mentioned. A substantial share of the primary literature originates from one research group — Predrag Sikirić’s laboratory in Zagreb and its collaborators, who first reported the compound in 1993 and have published on it continuously since.

This is not an accusation. Pioneering groups often dominate the early literature on a compound they discovered, and productivity is not misconduct. But independent replication is what converts a finding into knowledge, and a literature concentrated in one group has had less of it than its volume suggests. Counting papers overstates how much independent confirmation exists.

What was studied, and in what

Reported preclinical work spans several areas, consistently in animal models or cell culture:

Area	Representative citation
Gastrointestinal mucosal models	Sikiric P, et al. Curr Pharm Des. 2011
Tendon cell and tendon models	Chang CH, et al. J Appl Physiol. 2011; Staresinic M, et al. J Orthop Res. 2003
Ligament models	Cerovecki T, et al. J Orthop Res. 2010
Brain–gut axis	Sikiric P, et al. Curr Neuropharmacol. 2016
Pharmacokinetics, rats and dogs	He L, et al. Front Pharmacol. 2022
Preclinical safety evaluation	Xu C, et al. Regul Toxicol Pharmacol. 2020
Detection and in vitro metabolism	Cox HD, Miller GD, Eichner D. Drug Test Anal. 2017

These describe observations in specific models under specific conditions. They are not descriptions of effects in people, and nothing in them should be read as such.

What does not exist

As important as the list above, and routinely omitted:

No regulatory approval in any country, for any indication.
No completed, reported controlled human trial. A Phase I study in healthy volunteers was undertaken; its results were never submitted.
No human safety data of the kind the 2025 systematic review searched for and did not find.
No established mechanism. Angiogenic signaling, growth-factor pathways and nitric-oxide involvement have each been proposed; none is settled.
No pharmacovigilance record of the kind that accompanies an approved medicine.

A theoretical concern raised in the literature deserves a mention because it is the kind of thing enthusiasm tends to skip: a compound that promotes angiogenesis in a model raises questions about tissue where new vessel formation would be unwelcome. Whether that translates to any real-world risk is unknown, which is precisely the point — it is unstudied rather than excluded.

Regulatory status in 2026

BPC-157’s regulatory position changed in 2026 in a way that is widely misreported. Getting it right matters, because the misreading runs in the favorable direction.

It has never been approved anywhere. Not as a drug, not as a supplement, in no jurisdiction.

FDA placed it in Category 2. The agency’s interim 503A bulk drug substances categories sorted nominated substances, and BPC-157 sat in Category 2 — substances that may present significant safety risks. Compounding pharmacies were not to use it.

On April 15, 2026, FDA removed it from Category 2 — along with eleven others including Semax, Epitalon, KPV, LL-37, MOTS-c, TB-500 fragment and Melanotan II. Vendor sites have presented this as vindication. It is not, for two reasons the agency’s own notice makes clear.

First, the stated reason for removal was that the nominations were withdrawn by their nominators. FDA did not re-evaluate the substances and conclude they were safe. The nominations that put them on the list were pulled, so they came off it.

Second, and decisively, removal from Category 2 does not make a substance eligible for compounding under section 503A. FDA’s enforcement-discretion policy covers Category 1 substances only, and these twelve were not moved to Category 1. BPC-157 was also slated for Pharmacy Compounding Advisory Committee review following the removal. Its status is unresolved, not favorable — a procedural change in the opposite direction from how it is being sold.

Anti-doping. BPC-157 has been prohibited by the World Anti-Doping Agency since 2022 under category S0 — non-approved substances, which covers pharmacological substances with no current approval for human therapeutic use. S0 substances are prohibited at all times, in and out of competition. Verify the current Prohibited List directly, as it is revised annually.

Other jurisdictions. New Zealand and Australia have restricted BPC-157 as a prescription medicine, notwithstanding that no approved prescription product exists.

“Research use only” is not a shield. Under 21 CFR 201.128, intended use is determined from the objective intent of those responsible for labeling — advertising, statements and surrounding circumstances, assessed as a net impression rather than by the disclaimer alone.

Date	Action	What FDA cited
Dec. 2024 – Dec. 2025	Warning letters to Summit Research Peptides; Pinnacle Peptides	Website content establishing human-use intent despite research disclaimers
Mar. 31, 2026	Gram Peptides; Prime Sciences; Pink Pony Peptides; Mile High Compounds; PekCura Labs	Outcome claims notwithstanding RUO labeling
Apr. 8, 2026	Seven warning letters, five to RUO sellers	“Uses” statements, dosing instructions, outcome claims, clinical trial results quoted on product pages, bacteriostatic water sold alongside peptides
Aug. 24, 2026	Peak Performance Peptides; Royal Peptides; NuScience Peptides; Peptide Partners; TXP Innovations	Unapproved new drugs; RUO disclaimers rejected on a net-impression basis

The pattern is worth reading as a buyer rather than as a seller: a supplier whose BPC-157 page carries recovery or healing claims is operating in a posture FDA has acted on repeatedly, and enforcement that interrupts supply mid-study is a foreseeable risk.

This section is general information, not legal advice. Verify current status on FDA’s own pages.

Why the compound remains of research interest

Given everything above, the reasonable question is why anyone is still working on it.

Three honest answers. The preclinical signal is broad across model systems — gastrointestinal, musculoskeletal, vascular — which is unusual and is the kind of pattern that justifies mechanistic investigation even when it does not justify conclusions. The mechanism is genuinely unresolved, and unresolved mechanisms are what basic research exists to address. And the compound is synthetically accessible and analytically simple, with no disulfide to scramble and no oxidation-prone residues, which lowers the practical barrier to careful work.

What follows from that is a modest claim: BPC-157 is a reasonable subject for continued mechanistic investigation, and it is not a settled question in either direction. The 2025 review’s own framing — promising enough to study, insufficiently evidenced to recommend — is the defensible position, and it is a long way from how the compound is usually presented.

Documentation and handling

Reproducibility in this area depends on knowing what was actually in the vial. The general method is in our Research Peptide Supplier Evaluation Checklist; what follows is specific to this compound.

What a BPC-157 certificate should show. The compound named with its sequence; an expected mass or formula — ≈ 1419.6 g/mol, C₆₂H₉₈N₁₆O₂₂ — and a measured mass from LC-MS beside it; RP-HPLC purity with the chromatogram and the method parameters; net peptide content stated separately from purity; the lot number matching your vial; the testing laboratory named with a verifiable report reference; and analysis and manufacture dates. How to Read a COA works through each field, and HPLC vs. LC-MS explains why purity and identity are separate questions.

Content versus purity matters here. Net peptide content across synthetic peptides commonly lands in the 60–90% range of gross vial weight once counterions and bound water are accounted for. A concentration calculated from gross weight rather than net content will be systematically wrong, and the error is invisible.

Blends compound the problem. BPC-157 appears in multi-component research blends, and a single purity figure for a blend tells you little about the ratio of its components or the purity of each. Best Peptide Blend Suppliers in 2026 covers what a blend certificate needs to show; KLOW and GLOW describe two such compositions, and How Does TB-500 Work? covers a component common to both.

Handling. Equilibrate sealed vials to room temperature before opening, since lyophilized peptide is hygroscopic and a cold vial opened in a warm room condenses water onto the cake. Prepare single-use aliquots to avoid repeated freeze–thaw. Record lot, net content figure, solvent and date alongside your data — most irreproducibility traces to one of those being unrecorded rather than to anything exotic.

Our material. Peptides Exchange supplies BPC-157 10 mg as a research reagent, and it is a component of the KLOW and GLOW blends. Lot certificates are published on our Certificates of Analysis page, with independent testing by Freedom Diagnostics using HPLC-UV and LC-MS. Apply the checklist to those certificates rather than taking the method on faith; if a current lot’s certificate omits something you need, ask us for it.

All products are supplied for laboratory research use only and are not for human or animal consumption.

Frequently asked questions

What is BPC-157?

A synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, corresponding to a partial sequence of body protection compound, a protein identified in human gastric juice. Molecular formula C₆₂H₉₈N₁₆O₂₂, approximately 1419.6 g/mol, CAS 137525-51-0. First reported by Sikirić and colleagues in Zagreb in 1993.

How many human studies of BPC-157 exist?

Very few. The 2025 systematic review in HSS Journal screened 544 records and included 36 studies, of which 35 were preclinical and one was clinical — a retrospective series of 12 patients with chronic knee pain. The review found no human safety data. A Phase I study in healthy volunteers was undertaken but its results were never submitted.

Is BPC-157 FDA approved?

No. It is not approved in the United States or any other country, for any indication.

Why was BPC-157 removed from FDA’s Category 2 list?

On April 15, 2026, FDA removed BPC-157 and eleven other peptides from Category 2 of its interim 503A bulk drug substances categories, stating that the nominations had been withdrawn by their nominators. The agency did not re-evaluate the substances and find them safe. Removal from Category 2 does not make a substance eligible for compounding under section 503A, and BPC-157 was slated for advisory committee review following the change.

Is BPC-157 banned in sport?

Yes. The World Anti-Doping Agency has prohibited it since 2022 under category S0, non-approved substances, which applies at all times — in and out of competition. The list is revised annually and should be verified directly.

What does the systematic review conclude?

That the evidence is level IV to V, that heterogeneity prevented quantitative meta-analysis, that no human safety data were found, and that the absence of clinical outcome and safety data prevents evidence-based practice guidelines. Its stated conclusion is that clinicians and athletes should exercise caution.

Why is so much BPC-157 research from one group?

The compound was first reported by Predrag Sikirić’s laboratory in Zagreb in 1993, and that group and its collaborators have published on it continuously since. Pioneering groups commonly dominate the early literature on compounds they discovered. The relevant consequence is that counting publications overstates how much independent replication exists.

Does BPC-157 have stability advantages over other research peptides?

Structurally, it contains four proline residues, whose cyclic side chains constrain the backbone and resist cleavage by many proteases, and it has no cysteine or methionine — so no disulfide bridge to scramble and no oxidation-prone residue. That makes its analytical profile simpler than many peptides. It is a statement about chemistry, not about behavior in an organism.

What should a BPC-157 certificate of analysis show?

The compound and sequence, an expected mass or formula, a measured mass from LC-MS, RP-HPLC purity with the chromatogram and method parameters, net peptide content stated separately from purity, the lot number matching your vial, the testing laboratory with a verifiable report reference, and analysis and manufacture dates.

Why does a vial’s net peptide content matter?

Because purity and content answer different questions. Purity is the fraction of the peptide material that is the target molecule; content is the fraction of the vial’s gross weight that is peptide at all, the remainder being counterions, bound water and residual salts. A concentration calculated from gross weight rather than net content is systematically wrong.

For research and laboratory use only. Not for human or animal consumption. These materials are not drugs, foods, cosmetics or dietary supplements, and are not approved by FDA for any diagnostic, therapeutic or other use. Research findings described in this article are observations reported in specific experimental models and are not descriptions of effects in people. Peptides Exchange is a chemical supplier. It is not a compounding pharmacy as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and not an outsourcing facility as defined under section 503B. Nothing in this article is medical, legal or regulatory advice, and nothing in it describes or recommends use of any substance in humans or animals. Purchasers are responsible for compliance with applicable law and institutional safety requirements, and handling should be performed only by trained personnel.

Sources

Systematic and narrative reviews

Preclinical primary literature

Regulatory

Related reading in our Research Library

BPC-157: A Look at the Current State of Peptide Research